BetterLife Pharma Inc. (BETR:CC) | Stock Information | Vox Markets
Vox Markets

BetterLife Pharma Inc.

BETR:CC

Recent News

CompanyTitleDate
BETRBetterLife Pharma Announces Settlement of Claim with Dr. Steven Sangha1 day ago
BETRBetterLife Pharma Appoints Henry Chow, CPA, CA, to Board of Directors2 days ago
BETRBetterLife Pharma Appoints LifeSci Advisors as Investor Relations FirmOct 27, 2026
BETRBetterLife Pharma Appoints Professor Richard B. Lipton as Co-Chair of its Scientific Advisory BoardOct 19, 2026
BETRBetterLife Pharma Appoints Sheila Leitzinger as Head of Clinical OperationsOct 15, 2026
BETRBetterLife Pharma Establishes Scientific Advisory Board for Headache Program; Professor Peter Goadsby Appointed Co-ChairOct 14, 2026
BETRBetterLife Pharma Addresses Notice of Civil Claim Filed by Steven SanghaOct 9, 2026
BETRBetterLife Pharma Announces Rescheduling and Reclassification of Annual General Meeting to Annual General and Special MeetingSep 29, 2026
BETRBetterLife Pharma Inc. Announces Closing of US$100 Million Public Offering of Common Shares and Pre-Funded WarrantsSep 17, 2026
BETRBetterLife Pharma Inc. Announces Filing of Final Prospectus for US$100 Million Public Offering of Common Shares and Pre-Funded WarrantsSep 11, 2026
BETRBetterLife Pharma Appoints Charles Duncan as Director and Chair of the Audit CommitteeAug 31, 2026
BETRBetterLife Pharma Inc. Announces Pricing of US$100 Million Public Offering of Common Shares and Pre-Funded WarrantsAug 28, 2026
BETRBetterLife Pharma Inc. Announces Proposed Public Offering of Common Shares and Pre-Funded WarrantsAug 24, 2026
BETRBetterLife Pharma Appoints Mahan Chehrenama, DO, as Chief Medical OfficerAug 19, 2026
BETRBetterLife Pharma Prioritizes BETR-001 to Lead in Migraine and Headache Disorders, Targeting a Clinically Validated, FDA- Precedented Serotonergic MechanismJul 13, 2026
BETRBetterLife Pharma Announces Appointment of John W. LaRocca to Board of Directors and Audit CommitteeJul 9, 2026
BETRBetterLife Engages Nucro-Technics to Complete the last GLP Toxicology Study of BETR-001 Required by the FDA for IND and Phase 1Jul 6, 2026
BETRBetterLife Engages Syner-G to Oversee GMP Manufacturing of BETR-001 for IND and Phase 1Jun 25, 2026
BETRBetterLife Pharma Secures CAD $2 Million in New Capital to Complete BETR-001 FDA IND FilingJun 22, 2026
BETRBetterLife Pharma Announces Extension of WarrantsJun 19, 2026
Showing 1 to 20 of 41 results

Overview

Classification

Sector Healthcare

Industry Biotechnology & Life Sciences

Subindustry Biotechnology